SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Chainlink is the industry-standard decentralized oracle network that solves the "oracle problem" by connecting smart contracts with real-world data. Blockchains cannot access external information on their own, so Chainlink acts as a secure bridge, enabling smart contracts to react to real-world events using verified, tamper-proof data. It is widely considered one of the first decentralized oracle networks and is the market leader in bringing off-chain data on-chain.  The platform operates through a decentralized network of nodes that fetch, validate, and deliver data to smart contracts. When a contract requests information like a stock price, a committee of independent nodes retrieves and aggregates the data to reach consensus, then delivers a single trustworthy answer. Chainlink offers a suite of services including Data Feeds for asset prices, CCIP for cross-chain token transfers and messaging, Automation for triggering smart contract functions, and Proof of Reserve for verifying asset collateralization.  Chainlink has established itself as critical infrastructure for both DeFi and institutional adoption, with partnerships including Swift, Euroclear, Mastercard, UBS, ANZ, Fidelity International, and J.P. Morgan. Its institutional products include the Chainlink Runtime Environment for tokenized asset workflows, Confidential Compute for privacy-preserving computation, and the Automated Compliance Engine for embedding regulatory rules into smart contracts.  The LINK token is the native asset used to pay node operators for services, fund subscription accounts, and incentivize network security through staking. Node operators stake LINK as collateral, which can be slashed if they provide inaccurate data. Chainlink was co-founded in 2017 by Sergey Nazarov and Steve Ellis, who co-authored the white paper with Ari Juels, and raised $32 million in its September 2017 ICO.

ChainLink

Chainlink is seeing heightened market attention driven by its critical role as the infrastructure layer for real-world asset tokenization and institutional financial integration. The community remains focused on potential regulatory tailwinds, such as the Clarity Act, while debating the long-term price correlation between its expanding utility as an oracle network and its token valuation.

Melania memes are digital collectibles intended to function as an expression of support for and engagement with the values embodied by the symbol MELANIA

Melania Trump

The Melania crypto token continues to see intense community backlash as traders widely characterize it as a scam, fueling ongoing debate and heated criticism regarding its lack of utility. Investors are actively discussing the token's significant price decline and the broader pattern of political-themed meme coins that have faced similar allegations of being pump-and-dump schemes.

What is the project about? Pepe is a community based meme token surround the iconic meme Pepe the frog. Pepe aims to leverage the power of such an iconic meme to become the most memeable memecoin in existence.   What makes your project unique? Pepe is here to make memecoins great again. Ushering in a new paradigm for memecoins, Pepe represents the memecoin in it's purest simplicity. With zero taxes, liquidity locked forever, and contract immutable, Pepe is for the people, forever. Pepe is about culture, rallying together a community to have fun and enjoy memes, fueled purely by memetic power.   History of your project. Pepe was stealth launched on Friday, April 14th, 2023.   What’s next for your project? Pepe will focus on developing a tight-knit community around the token and building resources to enrich the communities knowledge and success in crypto through a token gated group, newsletter, and more tools.   What can your token be used for? Pepe can be used to speculate on the power of memes, and does not pretend to be anything more.

Pepe

Pepe is currently drawing intense community debate as traders split between bullish optimism for a potential meme cycle breakout and skepticism over its recent price stagnation. The discourse is heavily driven by retail investors debating whether to hold through current market volatility or rotate into alternative meme tokens.

Curaleaf Holdings, Inc. operates as a holding company with interest in medical and wellness cannabis operations. It operates through the Domestic Operations and International Operations segments. The company was founded on November 13, 2014 and is headquartered in Stamford, CT.

Curaleaf Holdings Inc

Curaleaf is in the spotlight following the announcement of a takeover bid for Aurora Cannabis, a move that has sparked community debate over potential synergies and valuation concerns. Investors are actively discussing the implications for sector-wide M&A trends as they weigh the company's international footprint and market leadership against ongoing regulatory and economic headwinds.

Freddie Mac engages in the provision of housing finance system solutions. It operates through the Single-Family and Multifamily segments. The Single-Family segment is involved in purchase, securitization, and guarantee of single-family loans, investments, and management of single-family mortgage credit risk and market risk. The Multifamily segment focuses on purchase, securitization, and guarantee of multifamily loans, investments, securities, and management of multifamily mortgage credit risk and market risk. The company was founded on July 24, 1970 and is headquartered in McLean, VA.

Federal Home Loan Mortgage Corp

Freddie Mac

Freddie Mac (FMCC) and Fannie Mae (FNMA) are trending as investors analyze signals regarding their potential exit from government conservatorship, including recent leadership commentary, institutional activity, and the possibility of a taxpayer-backed IPO. The community remains heavily focused on the prospect of relisting on major exchanges, with many shareholders maintaining long-term positions while debating the timing of government policy shifts.

What is Amp?  Amp is described as the new digital collateral token offering instant, verifiable assurances for any kind of value transfer. Using Amp, networks like Flexa can quickly and irreversibly secure transactions for a wide variety of asset-related use cases.  How does Amp work?  Amp claims to offer a straightforward but versatile interface for verifiable collateralization through a system of collateral partitions and collateral managers. Where collateral partitions can be designated to collateralize any account, application, or even transaction, and carry balances which are directly verifiable on the Ethereum blockchain, collateral managers are smart contracts that can lock, release, and redirect collateral in these partitions as needed in order to support value transfer activities. Amp supports a wide variety of use cases for collateralization, and also introduces the concept of predefined partition strategies, which can enable special capabilities such as collateral models through which tokens can be staked without ever leaving their original address.

AMP Token

AMP is trending as investors debate its long-term utility in digital payment infrastructure versus its ongoing price decline and management silence. While some community members are actively accumulating during this low-price period, others are vocalizing deep frustration over stagnant performance and questioning the project's transparency.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is currently in the spotlight as investors speculate on the long-term potential of its oral drug candidate, soquelitinib, following positive analyst coverage and upcoming data presentations. While some community members are highlighting institutional accumulation and the potential for a short squeeze, others remain cautious due to the company's early-stage development and history of cash burn.

Immuneering Corp. operates as a clinical-stage oncology company, which engages in developing medicines for cancer patients. Its pipeline of drug candidates focuses on treating aspects of disease that have eluded conventional approaches, including cancer cachexia and metastasis. The company was founded by Robert J. Carpenter and Benjamin J. Zeskind in 2008 and is headquartered in Cambridge, MA.

Immuneering Corp - Ordinary Shares Class A

Immuneering Corp

Immuneering is currently trending as investors focus on its atebimetinib oncology platform, driven by compelling survival data in pancreatic cancer and anticipation surrounding upcoming data presentations at the ASCO annual meeting. Community discussions emphasize the company's favorable risk-reward profile and significant cash runway, while contrasting its valuation with larger peers in the space.

Xanadu Quantum Technologies Ltd. engages in the provision of quantum computing solutions for enterprise and government customers. The company was founded by Christian Weedbrook on October 2, 2025 and is headquartered in Toronto, Canada.

Xanadu Quantum Technologies Ltd. - Ordinary Shares - Class B (Sub Voting)

Xanadu Quantum Technologies is driving significant community discussion as investors speculate on potential Canadian government funding while debating the company's long-term photonic technology prospects. Market participants are closely watching for updates on proposed support packages, with sentiment split between those viewing the firm as a speculative growth play and critics focused on its cash burn and dilution risks.

Cadence Design Systems, Inc. engages in the provision of design and development of integrated circuits and electronic devices. It operates through the following geographical segments: Americas, Asia, EMEA, and Japan. The company was founded by Alberto Sangiovanni-Vincentelli, Gudmundur A. Hjartarson, K. Bobby Chao, and K. Charles Janac in June 1988 and is headquartered in San Jose, CA.

Cadence Design Systems, Inc.

Cadence Design Systems is trending as shares surged following news that U.S. export restrictions on chip design software to China have been rescinded, easing concerns about revenue exposure in a key market. Investors are actively discussing the company's status as a critical 'pick and shovel' play in the semiconductor space, with many highlighting its duopolistic position and the long-term tailwinds provided by rising demand for AI-integrated design solutions.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Perceptive Advisors Llc Sells 31,810 Shares of Lyra Therapeutics (NASDAQ:LYRA) Stock

Lyra Therapeutics, Inc. (NASDAQ:LYRA - Get Free Report) major shareholder Perceptive Advisors Llc sold 31,810 shares of the stock in a transaction on Thursday, November 13th. The stock was sold at an...

Lyra Therapeutics, Inc. (LYRA) Reports Q3 Loss, Lags Revenue Estimates

Lyra Therapeutics (LYRA) delivered earnings and revenue surprises of +43.48% and -77.27%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Lyra Therapeutics (NASDAQ:LYRA) Major Shareholder Perceptive Advisors Llc Sells 32,149 Shares

Lyra Therapeutics, Inc. (NASDAQ:LYRA - Get Free Report) major shareholder Perceptive Advisors Llc sold 32,149 shares of Lyra Therapeutics stock in a transaction on Thursday, November 6th. The shares...

Assertio (ASRT) Surpasses Q3 Earnings and Revenue Estimates

Assertio (ASRT) delivered earnings and revenue surprises of +237.50% and +83.86%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Dentsply International (XRAY) Lags Q3 Earnings Estimates

Dentsply (XRAY) delivered earnings and revenue surprises of -17.78% and +0.27%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Heron Therapeutics (HRTX) Reports Q3 Loss, Misses Revenue Estimates

Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -150.00% and -0.91%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Lyra Therapeutics To Conduct One More Trial For Chronic Rhinosinusitis Treatment Candidate

Equity

The company stated that the design of the new trial will be based on the learnings from the previous trials, in addition to FDA feedback.

Lyra Therapeutics, Inc. (LYRA) Reports Q2 Loss, Beats Revenue Estimates

Lyra Therapeutics (LYRA) delivered earnings and revenue surprises of +4.84% and +26.21%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Heron Therapeutics (HRTX) Reports Q2 Loss, Misses Revenue Estimates

Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -100.00% and -1.89%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Lyra Therapeutics (LYRA) Upgraded to Buy: Here's Why

Lyra Therapeutics, Inc. is a clinical-stage therapeutics company. It develops novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat (ENT) diseases. The firm's proprietary XTreo platform delivers medicines directly to targeted sites. The company was founded by Carmichael S. Roberts, George M. Whitesides, and Robert S. Langer on November 21, 2005 and is headquartered in Watertown, MA.

Lyra Therapeutics Inc

Bullish Sentiment

Up more than 1% 

Flat to up 1%

Flat to down 1%

Down more than 1%

The S&P 500 ($SPY) is headed towards a winning week. What do you think the index's return will look like next week? Vote and explain your reasoning in the comments.

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$0.25
Prev Close	$0.25
Open	$0.15
Dividend Yield	0.00%
50-Day Moving Average	$0.5326
Beta	-0.27
Avg. Volume	12,249.77
PE Ratio	-0.01

52-Week High	$8.75
52-Week Low	$0.0004
Market Capitalization	$443,720.00
EPS (Annual)	-$18.62
Price to Book	-0.04
Revenue Per Employee	$14,740.74

Feed

News

Sentiment

Earnings

Fundamentals

Info